Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lambda-bis(2,2'-bipyridine)imidazole osmium (II) is an experimental small molecule complex containing an osmium(II) metal center coordinated by two 2,2'-bipyridine ligands and one imidazole ligand. It belongs to the class of organic compounds known as pyridines and derivatives. The compound has a molecular formula of C23H19N6Os and a molecular weight of approximately 569.7 g/mol[1][3][10]. While detailed pharmacological data are not available, related osmium polypyridyl complexes have been studied for their photophysical properties, DNA binding affinity, and potential antiproliferative activity in cancer models due to their ability to interact with nucleic acids and disrupt cellular processes[6][8]. However, there are no approved indications or clinical trials for this specific compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lambda-bis(2,2'-bipyridine)imidazole osmium (II).